Who
Allison Ambrose
General Counsel
Company insider
Files Form 4 as: General Counsel, Upstream Bio.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $20K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Dec 2024
- Last trade
- 16 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 17 Sep 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $2,663485 at $5.49 | filing |
| 16 Sep 2026filed 17 Sep 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $2,663485 at $5.49 | filing |
| 16 Jun 2026filed 17 Jun 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $2,910477 at $6.10 | filing |
| 16 Jun 2026filed 17 Jun 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $2,910477 at $6.10 | filing |
| 16 Mar 2026filed 17 Mar 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $4,413475 at $9.29 | filing |
| 16 Mar 2026filed 17 Mar 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $4,413475 at $9.29 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 6 Feb 2025filed 7 Feb 2025 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 16 Dec 2024filed 17 Dec 2024 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewUPB · dailypolitical.com · 13 Oct 2026Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)UPB · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Allison Ambrose; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.